ARTICLE | Product Development
Positives outnumber negatives among recent clinical results
Enlivex shows benefit in OA, Remegen meets Phase III Sjogren’s endpoint, and more, in BioCentury’s Clinical Report
August 22, 2025 12:15 AM UTC
The past week delivered a wave of stock-moving clinical updates, most of them positive. The biggest mover was Rocket Pharmaceuticals Inc. (NASDAQ:RCKT), which posted gains after FDA lifted a clinical hold on its rare disease gene therapy trial.
Other positive updates include a Phase III readout from Remegen Co. Ltd. (HKEX:9995; Shanghai:688331) that helps build the case for BAFF/APRIL inhibitors in Sjogren’s disease, and evidence from Enlivex Therapeutics Ltd. (NASDAQ:ENLV) showing that its allogeneic, apoptotic cell therapy improved both pain and function in patients with knee osteoarthritis. ...